SCHEMBL10132074

SCHEMBL10132074

O=C(CCOCCOCCOCCOCCOCCC(=O)NC1CC1)NC1CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 2/20 0.47
HPGD P15428 3/20 0.46
CNR1 P21554 4/20 0.45
CNR2 P34972 4/20 0.45
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
NCOR2 Q9Y618 1/20 0.44
MAPT P10636 2/20 0.44
SMYD3 Q9H7B4 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13708640 0.90 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1HPGDCNR1CNR2
SCHEMBL12094076 0.85 RAB9A (0.48) SMN1; SMN2MAPTNPSR1
SCHEMBL12094075 0.85 NPSR1 (0.42) SMN1; SMN2ALDH1A1CNR1CNR2MAPT
SCHEMBL23157621 0.82 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL20927250 0.82 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1HPGDCNR1CNR2
SCHEMBL25030411 0.82 SMYD3 (0.42) SMN1; SMN2ALDH1A1HPGDCNR1CNR2
SCHEMBL26201847 0.82 SMYD3 (0.42) SMN1; SMN2ALDH1A1HPGDCNR1CNR2
SCHEMBL14163196 0.81 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL25030885 0.81 NPSR1 (0.40) SMN1; SMN2ALDH1A1HPGDCNR1CNR2
SCHEMBL26062862 0.81 NPSR1 (0.40) SMN1; SMN2ALDH1A1HPGDCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A SMN1; SMN2 4722/4885ALDH1A1 4835/4885HPGD 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.